Alnylam Pharmaceuticals I... (ALNY)
Company Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).
In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH.
Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.
Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics.
It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc.
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Country | United States |
IPO Date | Jun 1, 2004 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2,230 |
CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. |
Contact Details
Address: 675 West Kendall Street Cambridge, Massachusetts United States | |
Website | https://www.alnylam.com |
Stock Details
Ticker Symbol | ALNY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001178670 |
CUSIP Number | 02043Q107 |
ISIN Number | US02043Q1076 |
Employer ID | 77-0602661 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Yvonne L. Greenstreet M.B.A., M.D. | Chief Executive Officer & Director |
Jeffrey V. Poulton M.B.A. | Chief Financial Officer & Executive Vice President |
Robert W. Hesslein Esq., J.D. | Executive Vice President, Chief Legal Officer & Corporate Secretary |
Christine Regan Lindenboom | Chief Corporate Communications Officer |
Dr. Kevin Joseph Fitzgerald Ph.D. | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development |
Dr. Phillip A. Sharp Ph.D. | Co-Founder, Member of the Scientific Advisory Board & Independent Director |
Dr. Pushkal P. Garg M.D. | Chief Medical Officer and Executive Vice President of Development & Medical Affairs |
Piyush Sharma J.D. | Chief Ethics & Compliance Officer |
Timothy J. Maines | Chief Technical Operations & Quality Officer |
Tolga Tanguler M.B.A. | Executive Vice President & Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2025 | 4 | Filing |
Mar 25, 2025 | 4 | Filing |
Mar 24, 2025 | ARS | Filing |
Mar 24, 2025 | DEFA14A | Filing |
Mar 24, 2025 | DEF 14A | Filing |
Mar 21, 2025 | 8-K | Current Report |
Mar 14, 2025 | 4 | Filing |
Mar 14, 2025 | PRE 14A | Filing |
Mar 05, 2025 | 8-K | Current Report |
Mar 05, 2025 | 4 | Filing |